Pharmacy Times October 2009


Drug Interactions: Insights and Observations


The Effect of Hepatic Disease on Drug Interactions


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD





1.     Orlando R, Piccoli P, De Martin S et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther. 2004;75:80-8.

2.     Orlando R, Padrini R, Perazzi M, et al. Liver dysfunction markedly decreased the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther. 2006;79:489-99.

3.     Orlando R, De Martin S, Pegoraro P et al. Irreversible CYP3A4 inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther. 2009;85:319-26.

4.     Horn JR and Hansten, PD. Understanding an important variable in patient response. Pharmacy Times. 2006; Sept: 84.

5.     McConn II DJ, Lin YS, Mathisen TL, et al. Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. Clin Pharmacol Ther. 2009;85:387-93.